Geron good article Seeking Alpha

This was in Seeking Alpha today: Consider These 3 Biotech Stocks for Potential Growth.
Geron was established in 1990 and completed its IPO in 1996. It is unusual to see a biotech company which has survived for that length of time without a product on the market. Most biotech companies in this position either fail or get acquired. Geron started out by focusing on stem cell treatments as well as oncology treatments, but decided to abandon stem cell research in 2011 due to the high cost of working on both, and decided to focus solely on oncology. It is working on the disposal of its stem cell assets, but there has been no progress reported so far. The company has two oncology drugs under development which have the potential to revolutionize cancer treatment if they are successful. The company has six Phase 2 trials currently underway.
The company's first, and most advanced drug, is called Imetelstat, a telomerase inhibitor which is currently in Phase 2 trials. Telomerase is the enzyme that enables cells to divide indefinitely without becoming unstable, thus allowing tumors to grow. There is plenty of scientific evidence to indicate that the enzyme is a key factor in the development of cancer. Geron is not the only company working on telomerase inhibitors, but it is the most advanced. Its strategy for cancer treatment is to stop or inhibit the growth of tumors. Imetelstat is currently in trials for the treatment of four different types of cancer, including breast cancer, NSCLC (non-small cell lung cancer) for solid tumors, multiple myeloma, and essential thrombocythemia for malignancies related to hematology. The data from all four trials is expected to become available over the next twelve months.
GRN1005 is an LRP-directed peptide drug combination aimed at treating brain cancer, which is currently very difficult to treat, because existing cancer drugs cannot penetrate the barrier between circulating blood in the body and the fluids of the brain. GRN1005 uses the LRP-1 transport mechanism, which uses a particular protein to bypass the blood-brain barrier and deliver cancer drugs to the brain. GRN1005 is now in Phase 2 trials to test the effectiveness of treatment in breast and lung cancer that has spread to the brain.
Geron's approach to oncology is unique, and positive results from any of the trials could potentially boost the price of the stock. Conversely, there is also limited protection for the stock price because of the number of trials that are in progress simultaneously. Additionally, failure in one trial may be construed as a possible failure in other trials utilizing the same drug which could be catastrophic for the share price. I urge risk tolerant investors interested in Geron to conduct further research and be prepared to hold for twelve months or longer.

I've beed staying this for months. If Geron hits I'm rich if they miss, it's work till I drop.

Good luck in this rigged casino,